Millennium Management’s TCR2 Therapeutics Inc. Common Stock TCRR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-31,683
| Closed | -$48K | – | 7049 |
|
|
2023
Q1 | $48K | Sell |
31,683
-108,358
| -77% | -$146K | ﹤0.01% | 5640 |
|
|
2022
Q4 | $140K | Sell |
140,041
-128,089
| -48% | -$173K | ﹤0.01% | 5469 |
|
|
2022
Q3 | $483K | Sell |
268,130
-50,286
| -16% | -$146K | ﹤0.01% | 5007 |
|
|
2022
Q2 | $923K | Buy |
318,416
+218,947
| +220% | +$540K | ﹤0.01% | 4435 |
|
|
2022
Q1 | $275K | Sell |
99,469
-1,345,848
| -93% | -$4.23M | ﹤0.01% | 5619 |
|
|
2021
Q4 | $6.74M | Buy |
1,445,317
+1,156,650
| +401% | +$7.23M | ﹤0.01% | 2592 |
|
|
2021
Q3 | $2.46M | Buy |
288,667
+272,860
| +1,726% | +$3.86M | ﹤0.01% | 3667 |
|
|
2021
Q2 | $259K | Sell |
15,807
-132,536
| -89% | -$2.68M | ﹤0.01% | 5844 |
|
|
2021
Q1 | $3.27M | Sell |
148,343
-336,585
| -69% | -$9.18M | ﹤0.01% | 3043 |
|
|
2020
Q4 | $15M | Sell |
484,928
-176,173
| -27% | -$4.45M | 0.01% | 1313 |
|
|
2020
Q3 | $13.4K | Buy |
661,101
+621,171
| +1,556% | +$10.9M | 0.02% | 1036 |
|
|
2020
Q2 | $613K | Sell |
39,930
-31,168
| -44% | -$360K | ﹤0.01% | 3281 |
|
|
2020
Q1 | $550K | Buy |
71,098
+20,886
| +42% | +$256K | ﹤0.01% | 2823 |
|
|
2019
Q4 | $717K | Buy |
+50,212
| New | +$776K | ﹤0.01% | 3162 |
|
|
2019
Q3 | – | Sell |
-141,435
| Closed | -$2.02M | – | 4666 |
|
|
2019
Q2 | $2.02M | Sell |
141,435
-99,203
| -41% | -$1.58M | ﹤0.01% | 2393 |
|
|
2019
Q1 | $4.19M | Buy |
+240,638
| New | +$4.27M | 0.01% | 1891 |
|
Millennium Management's TCRR Position: Q2 2023 in Review
Millennium Management sold out of TCR2 Therapeutics Inc. Common Stock (TCRR) in Q2 2023, closing a stake of 31,683 shares — an estimated $48K sold.
Millennium Management first reported a position in TCRR in Q1 2019 and held it in 16 quarters. The position peaked at $15M in Q4 2020. 0 funds tracked by Wall St. Rank hold TCRR as of Q2 2023.
- Millennium Management reported no remaining TCR2 Therapeutics Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- Millennium Management sold 31,683 TCR2 Therapeutics Inc. Common Stock shares in Q2 2023, an estimated $48K.
- Millennium Management first reported a position in TCR2 Therapeutics Inc. Common Stock in Q1 2019 and held it in 16 quarters.
- Millennium Management's TCR2 Therapeutics Inc. Common Stock position peaked at $15M in Q4 2020.
- 0 funds tracked by Wall St. Rank held TCR2 Therapeutics Inc. Common Stock as of Q2 2023.
Based on Millennium Management's 13F filing for Q2 2023, filed 14 Aug 2023.